Using AI-Powered Models and Drug-Response Data, Pr
Post# of 281
(Total Views: 247)
Posted On: 12/15/2020 4:15:52 PM
Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry
- Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy
- Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report
- POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery
Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72 billion by 2027 as a result of synergistic efforts between big data healthcare organizations and pharmaceutical companies (https://nnw.fm/TMd4u). Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery for cancer, is positioned to play a critical role in industry growth through its integration of AI technology into oncologists’ clinical decision-making processes, paving the way for better health outcomes.
Recent advances in cancer care have been closely associated with genomic medicine, fueled by research confirming correlations between specific genetic mutations and several tumors and tumor types. These advances hold promise for oncologists who use genomic testing to look for genetic mutations in patients when determining the most appropriate treatment options for their patients.
POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (“CLIA”)-certified lab, a “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options
The growth of precision medicine in cancer therapeutics has been driven in recent years by analysis of patients and tumors mutations and their responses to pharmaceutical treatments. The process is both resource and time-sensitive, often requiring years of clinical evaluation and observation to produce data that determines treatment efficacy tied to a particular therapy
POAI is ahead of the curve through its vast collection of tumors, their related data, the company’s ability to access associated outcome data, and the application of AI to more than 150,000 tumors in its database. Along with assisting oncologists in prescribing precision cancer treatments, POAI’s data-driven approach propels research forward for the development of drug therapies through the company’s collaborations with pharmaceutical companies.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy
- Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report
- POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery
Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72 billion by 2027 as a result of synergistic efforts between big data healthcare organizations and pharmaceutical companies (https://nnw.fm/TMd4u). Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery for cancer, is positioned to play a critical role in industry growth through its integration of AI technology into oncologists’ clinical decision-making processes, paving the way for better health outcomes.
Recent advances in cancer care have been closely associated with genomic medicine, fueled by research confirming correlations between specific genetic mutations and several tumors and tumor types. These advances hold promise for oncologists who use genomic testing to look for genetic mutations in patients when determining the most appropriate treatment options for their patients.
POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (“CLIA”)-certified lab, a “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options
The growth of precision medicine in cancer therapeutics has been driven in recent years by analysis of patients and tumors mutations and their responses to pharmaceutical treatments. The process is both resource and time-sensitive, often requiring years of clinical evaluation and observation to produce data that determines treatment efficacy tied to a particular therapy
POAI is ahead of the curve through its vast collection of tumors, their related data, the company’s ability to access associated outcome data, and the application of AI to more than 150,000 tumors in its database. Along with assisting oncologists in prescribing precision cancer treatments, POAI’s data-driven approach propels research forward for the development of drug therapies through the company’s collaborations with pharmaceutical companies.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼